Maegim한국어

큐라클

365270KOSDAQSector: Pharma & Biotech
₩8,430 1.20%Market cap ₩186.8BAs of Jul 21, 2026 close · updated once daily
D
Grade D25.7 ptsTop 91% of 2,523 stocks
Financial strength
31.8
Growth momentum
15.0
Price attractiveness
26.3

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

31.8
How much debt does it carry relative to equity?
Debt-to-equity ratio
43.5%
Above median · Top 40% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
192.3%
Above median · Top 49% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-232393.8%
Below median · Top 99.8% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-48.8%
Below median · Top 83.9% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original

2

Growth momentum

15.0
How much did revenue grow in a year?
Revenue growth (YoY)
-99.6%
Below median · Top 99.3% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
-87.4%
Below median · Top 99.7% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-30.6%
Below median · Top 76.6% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-37.7%
Below median · Top 64.2% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original

3

Price attractiveness

26.3
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 70.9% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
5.04x
Below median · Top 76.6% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15